Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients | Zendy

Isabelle Malet | Zendy; Marc Wirden | Zendy; Slim Fourati | Zendy; Daniele Armenia | Zendy; Bernard Masquelier | Zendy; Lavinia Fabeni | Zendy; Sophie Sayon | Zendy; Christine Katlama | Zendy; Carlo Federico Perno | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy; Francesca CeccheriniSilberstein | Zendy

Open Access

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Author(s) -

Isabelle Malet,

Marc Wirden,

Slim Fourati,

Daniele Armenia,

Bernard Masquelier,

Lavinia Fabeni,

Sophie Sayon,

Christine Katlama,

Carlo Federico Perno,

Vincent Cálvez,

AnneGeneviève Marcelin,

Francesca CeccheriniSilberstein

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr152

Subject(s) - raltegravir , integrase inhibitor , integrase , virology , biology , human immunodeficiency virus (hiv) , medicine , viral load , antiretroviral therapy

To compare the frequency of previously in vitro-selected integrase mutations (T124A, T124A/S153F, S153Y, T124A/S153Y and L101I/T124A/S153Y) conferring resistance to S/GSK1349572 between HIV-1 subtype B integrase inhibitor (INI)-naive and raltegravir-treated patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research